The securities of Suda Pharmaceuticals Ltd (‘SUD’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of SUD, pending the release of an announcement regarding a proposed licensing transaction and a capital raising.
For more information, download the attached PDF.
Download this document
